Please assess the completion status of the following clinical trial:

Trial Title: Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Neonate (\< 28 days old) undergoing correct cardiac surgery, or infants undergoing the following surgery procedures: Norwood, Arterial Switch, Total Anomalous Pulmonary Venous Return Repair, Interrupted Aortic Arch Repair, Truncus Arteriosus Repair~2. Successfully weaned off cardiopulmonary bypass after cardiac surgery~Exclusion Criteria:~1. requirement for extracorporeal membrane oxygenation (ECMO) in the operating room~2. Known immune deficiency~3. Having previously received systemic steroids (except for two routine preoperative doses)~4. A current signed Do not resuscitate (DNR) or limitation of care order~5. Current enrollment in another interventional clinical study~6. Refusal of parental consent~7. Previous diagnosis of adrenal insufficiency~8. \> 28 days old at time of surgery whose repair dose not require CPB

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
- Hydrocortisone (Type: EXPERIMENTAL): Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).